August 4, 2022 (v1)
Journal article
Background: Dupilumab is the first biotherapy available for the treatment of moderate-to-severe childhood atopic dermatitis (AD).Objective: The aim of this study was to evaluate the effectiveness and safety of dupilumab in daily practice.Methods: Patients aged 6-11, who had received a first dose of dupilumab, were included in this multicentre...
Uploaded on: February 11, 2024